Dyslipidemia and Diabetes – Standards of Medical Care

What’s new in lipid management for people with diabetes or metabolic syndrome?

Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine.

This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with diabetes or who suffer from metabolic syndrome. Our experts also dive into the topics of why this patient subgroup is particularly at higher risk for cardiovascular complications, and how timely intensification of lipid-lowering therapy, through statin optimization and use of agents such as PCSK9 inhibitors, can lead to better outcomes for such patients.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr.  Thanassoulis:

• Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence.

Dr. Manjoo:

• Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.